Medication Monitor



Generic Name (Trade Name—Company)
Notes
February 1, 2019

Fluticasone propionate and salmeterol inhalation powder

(Wixela Inhub—Mylan)
FDA approves first generic of Advair Diskus

FDA has approved the first generic of GlaxoSmithKline’s Advair Diskus—fluticasone propionate and salmeterol inhalation powder—for twice-daily treatment of asthma in patients aged 4 years and older and for maintenance treatment of airflow obstruction and reduction of exacerbations in patients with COPD.

The generic inhaler comes in three strengths: fluticasone propionate 100 mcg/salmeterol 50 mcg, fluticasone propionate 250 mcg/salmeterol 50 mcg, and fluticasone propionate 500 mcg/salmeterol 50 mcg.

The most common adverse effects of the inhaler for treatment of asthma are upper respiratory tract infection or inflammation, pharyngitis, dysphonia, oral candidiasis, bronchitis, cough, headaches, nausea, and vomiting.

For treatment of COPD, the most common adverse effects are pneumonia, oral candidiasis, throat irritation, dysphonia, viral respiratory infections, headaches, and musculoskeletal pain.